DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
SAN RAFAEL, Calif., Jan. 28, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 25, at 4:30 p.m. ET to discuss fourth quarter and full year 2015 financial results and provide a general business update.
Dial-in Number
U.S. / Canada Dial-in Number: (877) 303-6313
International Dial-in Number: (631) 813-4734
Conference ID: 34535772
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 34535772
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
